Your browser doesn't support javascript.
loading
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model.
VanScoy, Brian D; Lakota, Elizabeth A; Conde, Haley; McCauley, Jennifer; Friedrich, Lawrence; Steenbergen, Judith N; Ambrose, Paul G; Bhavnani, Sujata M.
Afiliação
  • VanScoy BD; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA BVanscoy@icpd.com.
  • Lakota EA; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
  • Conde H; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
  • McCauley J; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
  • Friedrich L; Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA.
  • Steenbergen JN; Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA.
  • Ambrose PG; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
  • Bhavnani SM; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Article em En | MEDLINE | ID: mdl-32284378
Omadacycline is a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including Haemophilus influenzae, which is one of the leading causes of community-acquired bacterial pneumonia (CABP). The evaluation of antimicrobial agents against H. influenzae using standard murine infection models is challenging due to the low pathogenicity of this species in mice. Therefore, 24-h dose-ranging studies using a one-compartment in vitro infection model were undertaken with the goal of characterizing the magnitude of the ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio) associated with efficacy for a panel of five H. influenzae isolates. These five isolates, for which MIC values were 1 or 2 mg/liter, were exposed to omadacycline total-drug epithelial lining fluid (ELF) concentration-time profiles based on those observed in healthy volunteers following intravenous omadacycline administration. Relationships between change in log10 CFU/ml from baseline at 24 h and the total-drug ELF AUC/MIC ratios for each isolate and for the isolates pooled were evaluated using Hill-type models and nonlinear least-squares regression. As evidenced by the high coefficients of determination (r2) of 0.88 to 0.98, total-drug ELF AUC/MIC ratio described the data well for each isolate and the isolates pooled. The median total-drug ELF AUC/MIC ratios associated with net bacterial stasis and 1- and 2-log10 CFU/ml reductions from baseline at 24 h were 6.91, 8.91, and 11.1, respectively. These data were useful to support the omadacycline dosing regimens selected for the treatment of patients with CABP, as well as susceptibility breakpoints for H. influenzae.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Streptococcus pneumoniae / Haemophilus influenzae Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Streptococcus pneumoniae / Haemophilus influenzae Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article